Alvine Pharmaceuticals

edit

Alvine Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing therapeutics for autoimmune/gastrointestinal diseases. Alvine’s lead product candidate, ALV003, is a combination protease engineered to digest gluten. It is being developed to treat patients with celiac disease.

Milestones

edit

• 
  Alvine Pharmaceuticals received $21.5M in Series A funding. (9/15/09)
  Posted 9/21/09 at 7:11am
• 
  Alvine Pharmaceuticals received $8M in Series A funding. (9/6/06)
  Posted 9/9/09 at 6:19am

Videos

Screenshots

edit

Sources

1. Alvine Pharma raises nearly $8M from Prospect, Sofinnova (deals.venturebeat.com) [edit]
2. Alvine gobbles $21.5M to treat gastrointestinal disease (deals.venturebeat.com) [edit]